Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare form of pulmonary hypertension (PH), a disease associated with abnormally high pressure in the blood vessels of the lungs, caused by the formation of blood clots. CTEPH also can be referred to as group 4 PH, the World Health Organization classification that…
Search results for:
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, underdiagnosed form of pulmonary hypertension caused by blood clots obstructing the pulmonary arteries. This obstruction restricts blood flow, potentially leading to right-sided heart failure. Early diagnosis is crucial, as CTEPH can be treated surgically.
AI-generated summaries are for informational use only, based on content from multiple pages. They may not reflect full context. For complete details, see the original sources. Consult a qualified healthcare professional for medical advice.
Social Clips
Thromboembolic Pulmonary Hypertension
“In this video, from the Texas Heart Institute, meet Deborah Meyers, MD, and her patient Trasetta Terry, a retired pharmacist who tells us about her experience with thromboembolic pulmonary hypertension.” Keep up to date on all the latest PH news here: https://bit.ly/20LXxHN…
A research journal recently reviewed the use of balloon pulmonary angioplasty (BPA), a new option for people with inoperable chronic thromboembolic pulmonary arterial hypertension. The work, titled “Balloon pulmonary angioplasty for inoperable chronic thromboembolic pulmonary hypertension“ appeared in the July 7, 2015 issue of…
Chronic Thromboembolic Pulmonary Hypertension (CTEPH) has been identified as one of the major causes of acute pulmonary hypertension (PH). This condition is characterized by a progressively dangerous accumulation of blood clots within pulmonary vasculature, which leads to PH and can eventually cause right-sided heart failure. It…
New research is shedding light on the progression of CTEPH. A novel study on chronic thromboembolic pulmonary hypertension (CTEPH), entitled “Comprehensive analysis of inflammatory markers in chronic thromboembolic pulmonary hypertension patients” published in the European Respiratory Journal by Dr. Diana Zabini, part…
The Pulmonary Hypertension Association (PHA) is planning a series of events for November, Pulmonary Hypertension Awareness Month, including a daylong focus on chronic thromboembolic pulmonary hypertension (CTEPH), a form of pulmonary hypertension (PH) that results from blood clots in the lungs. Events planned for CTEPH Awareness Day, Nov. 15, include promoting information about the two…
People with chronic thromboembolic pulmonary hypertension (CTEPH) are more likely to have a depressive temperament, finds a Japanese study, “Depressive Status in Patients With Chronic Thromboembolic Pulmonary Hypertension” that appeared in the Circulation Journal. CTEPH is a progressive disease characterized by increasing pulmonary vascular resistance. Although the underlying…
Social Clips
CTEPH: What You Need to Know
https://www.youtube.com/watch?v=W2YLo6U1uFU Pulmonary hypertension (PH) is a rare lung disease that refers to an increase in blood pressure in the pulmonary arteries. Unfortunately, there is still no known cure available to end PH, but research has been evolving and doctors and scientists have been discovering some new ways to approach this…
In this video from PHA Canada, meet Dr. Sanjay Mehta. Dr. Mehta is a CTEPH-treating doctor and in this clip shared in 2014, he discusses some important information on CTEPH and pulmonary hypertension. Read the latest updates on pulmonary hypertension: https://bit.ly/1K4oewk…
https://vimeo.com/184579437 In this video from Elsevier Pharma Solutions, Professor Marc Humbert discusses the diagnostic processes for pulmonary hypertension and chronic thromboembolic pulmonary hypertension (CTEPH)—which is a curable form of the disease. RELATED: A study find international diagnosis and management of CTEPH is inadequate. Prof. Hubert explains that CTEPH is…
Bayer Healthcare recently announced the approval of its novel drug Adempas (riociguat), which has been listed by the Régie de l’assurance malady du Québec (RAMQ), the Québec public formulary, as the one and only treatment option for patients with chronic thromboembolic pulmonary hypertension (CTEPH). Québec is the first province to provide Adempas…
For the first time, the long-term use of antipsychotic medications has been linked to the development of chronic thromboembolic pulmonary hypertension (CTEPH), a case study reports. The authors recommend that CTEPH should be considered in patients who receive antipsychotics and also have symptoms associated…